Jessica Fye
Stock Analyst at JP Morgan
(4.35)
# 286
Out of 5,182 analysts
216
Total ratings
58.52%
Success rate
14.11%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiates: Overweight | $30 | $19.42 | +54.48% | 1 | Feb 3, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $18.30 | +42.08% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $33.08 | -24.43% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $16.62 | +38.39% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $202.72 | -1.84% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $63.96 | +1.63% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $45.37 | -44.90% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $97.54 | +23.03% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $296.11 | +59.74% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $23.59 | +222.17% | 4 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $89 | $96.91 | -8.16% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $54.06 | +120.13% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $220.93 | +19.49% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $423.92 | +25.02% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $293.86 | +31.01% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $75.27 | +6.28% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $39.02 | +33.26% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $96.53 | -20.23% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $33.38 | +4.85% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $133.26 | +1.31% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $570.40 | -42.15% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $9.19 | +41.46% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $28.16 | +77.56% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $29.78 | +0.74% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $86.46 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.47 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $3.11 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $14.07 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.82 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.63 | +329.45% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.04 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.35 | - | 1 | Feb 8, 2018 |
Aktis Oncology
Feb 3, 2026
Initiates: Overweight
Price Target: $30
Current: $19.42
Upside: +54.48%
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $18.30
Upside: +42.08%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $33.08
Upside: -24.43%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $16.62
Upside: +38.39%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $202.72
Upside: -1.84%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $63.96
Upside: +1.63%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $45.37
Upside: -44.90%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $97.54
Upside: +23.03%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $296.11
Upside: +59.74%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $23.59
Upside: +222.17%
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $96.91
Upside: -8.16%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $54.06
Upside: +120.13%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $220.93
Upside: +19.49%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $423.92
Upside: +25.02%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $293.86
Upside: +31.01%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $75.27
Upside: +6.28%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $39.02
Upside: +33.26%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $96.53
Upside: -20.23%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $33.38
Upside: +4.85%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $133.26
Upside: +1.31%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $570.40
Upside: -42.15%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $9.19
Upside: +41.46%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $28.16
Upside: +77.56%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $29.78
Upside: +0.74%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $86.46
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.47
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $3.11
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $14.07
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.82
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.63
Upside: +329.45%
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.04
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $14.35
Upside: -